Anti-lung Cancer Effects of Polyphyllin VI and VII Potentially Correlate with Apoptosis In Vitro and In Vivo
Zhufen Lin
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorYuting Liu
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorFangyuan Li
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorJinjun Wu
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorGuiyu Zhang
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorYing Wang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorCorresponding Author
Linlin Lu
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Zhongqiu Liu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Linlin Lu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.
E-mail: [email protected] or [email protected] (Zhongqiu Liu); [email protected] (Linlin Lu)
Search for more papers by this authorCorresponding Author
Zhongqiu Liu
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Zhongqiu Liu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Linlin Lu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.
E-mail: [email protected] or [email protected] (Zhongqiu Liu); [email protected] (Linlin Lu)
Search for more papers by this authorZhufen Lin
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorYuting Liu
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorFangyuan Li
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorJinjun Wu
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorGuiyu Zhang
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorYing Wang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Search for more papers by this authorCorresponding Author
Linlin Lu
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Zhongqiu Liu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Linlin Lu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.
E-mail: [email protected] or [email protected] (Zhongqiu Liu); [email protected] (Linlin Lu)
Search for more papers by this authorCorresponding Author
Zhongqiu Liu
Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Zhongqiu Liu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Linlin Lu, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.
E-mail: [email protected] or [email protected] (Zhongqiu Liu); [email protected] (Linlin Lu)
Search for more papers by this authorAbstract
Polyphyllin VI (PVI) and polyphyllin VII (PVII) derived from Paris polyphylla possess anti-cancer activities. However, the mechanisms for the anti-lung cancer effects of PVI and PVII remain poorly understood. In this study, PVI and PVII exhibited inhibitory effects on the proliferation of A549 and NCI-H1299 cells. PVI and PVII induced G2/M cell cycle arrest and triggered apoptosis. PVI and PVII upregulated the tumor suppressor protein p53 and downregulated cyclin B1. The two treatments significantly increased the expression levels of death receptor 3, death receptor 5, Fas, cleaved PARP, and cleaved caspase-3. Furthermore, PVI and PVII significantly inhibited the growth of A549 cells in vivo. The tumor inhibitory rates of PVI were 25.74%, 34.62%, and 40.43% at 2, 3, and 4 mg/kg, respectively, and those of PVII were 25.63%, 41.71%, and 40.41% at 1, 2, and 3 mg/kg, respectively. Finally, PVI and PVII regulated the expression of proteins related to the apoptotic pathway in A549 xenografts. In summary, PVI and PVII exhibited strong inhibitory effects on lung cancer cell growth in vitro and in vivo by inducing G2/M cell cycle arrest and triggering apoptosis. Copyright © 2015 John Wiley & Sons, Ltd.
References
- Chen YS, He Y, Chen C, et al.. 2014. Growth inhibition by pennogenyl saponins from Rhizoma paridis on hepatoma xenografts in nude mice. Steroids 83: 39–44.
- Cheung JY, Ong RC, Suen YK, et al. 2005. Polyphyllin D is a potent apoptosis inducer in drug-resistant HepG2 cells. Cancer Lett 217(2): 203–211.
- Cozzi P. 2003. The discovery of a new potential anticancer drug: a case history. Farmaco 58(3): 213–220.
- Deng S, Yu B, Hui Y, Yu H, Han X. 1999. Synthesis of three diosgenyl saponins: dioscin, polyphyllin D, and balanitin 7. Carbohydr Res 317(1–4): 53–62.
- Erridge SC, Moller H, Price A, Brewster D. 2007. International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol 4(10): 570–577.
- Grundy JS, Eliot LA, Foster RT. 1997. Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 18(6): 509–522.
10.1002/(SICI)1099-081X(199708)18:6<509::AID-BDD38>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- Hahn O, Salgia R. 2007. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem 7(6): 633–642.
- Ho JW, Leung YK, Chan CP. 2002. Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents 2(2): 209–214.
- Lee MS, Yuet-Wa JC, Kong SK, et al. 2005. Effects of polyphyllin D, a steroidal saponin in Paris polyphylla, in growth inhibition of human breast cancer cells and in xenograft. Cancer Biol Ther 4(11): 1248–1254.
- Li B, Yu B, Hui Y, Li M, Han X, Fung KP. 2001. An improved synthesis of the saponin, polyphyllin D. Carbohydr Res 331(1): 1–7.
- Li Y, Fan L, Sun Y, et al. 2014. Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation. J Ethnopharmacol 154(3): 728–734.
- Man S, Gao W, Zhang Y, et al. 2009. Characterization of steroidal saponins in saponin extract from Paris polyphylla by liquid chromatography tandem multi-stage mass spectrometry. Anal Bioanal Chem 395(2): 495–505.
- Man S, Gao W, Yan Y, Liu Z, Liu C. 2011. Inhibition of matrix metalloproteinases related to metastasis by diosgenyl and pennogenyl saponins. J Ethnopharmacol 137(3): 1221–1227.
- Mann J. 2002. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2(2): 143–148.
- Marsters SA, Sheridan JP, Pitti RM, et al. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7(12): 1003–1006.
- Ong RC, Lei J, Lee RK, et al. 2008. Polyphyllin D induces mitochondrial fragmentation and acts directly on the mitochondria to induce apoptosis in drug-resistant HepG2 cells. Cancer Lett 261(2): 158–164.
- Paz-Ares L, Corral J. 2014. Treatment for early-stage lung cancer: what next? Lancet 383(9928): 1528–1530.
- Pitti RM, Marsters SA, Lawrence DA, et al. 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396(6712): 699–703.
- Ramnath N, Dilling TJ, Harris LJ, et al. 2013. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl): e314S–340S.
- Siu FM, Ma DL, Cheung YW, et al. 2008. Proteomic and transcriptomic study on the action of a cytotoxic saponin (Polyphyllin D): induction of endoplasmic reticulum stress and mitochondria-mediated apoptotic pathways. Proteomics 8(15): 3105–3117.
- Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. 2009. Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8: 8.
- Wang B, Ji S, Zhang H, et al. 2013. Liquid chromatography tandem mass spectrometry in study of the pharmacokinetics of six steroidal saponins in rats. Steroids 78(12–13): 1164–1170.
- Wen F, Yin H, Chen C, et al. 2012. Chemical characteristics of saponins from Paris fargesii var. brevipetala and cytotoxic activity of its main ingredient, paris saponin H. Fitoterapia 83(4): 627–635.
- Wu S, Gao W, Qiu F, Man S, Fu S, Liu C. 2012. Simultaneous quantification of Polyphyllin D and Paris H, two potential antitumor active components in Paris polyphylla by liquid chromatography-tandem mass spectrometry and the application to pharmacokinetics in rats. J Chromatogr B Analyt Technol Biomed Life Sci 905: 54–60.
- Xiao X, Bai P, Bui Nguyen TM, et al. 2009. The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther 8(5): 1179–1188.
- Xiao X, Zou J, Bui-Nguyen TM, et al. 2012. Paris saponin II of Rhizoma paridis—a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends 6(4): 201–211.
- Xiao X, Yang M, Xiao J, et al. 2014. Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration. Cancer Chemother Pharmacol 73(4): 807–818.
- Yan LL, Zhang YJ, Gao WY, Man SL, Wang Y. 2009. In vitro and in vivo anticancer activity of steroid saponins of Paris polyphylla var. yunnanensis. Exp Oncol 31(1): 27–32.
- Zeng QY, Zeng LJ, Huang Y, Huang YQ, Zhu QF, Liao ZH. 2014. 8-60hIPP5(m)-induced G2/M cell cycle arrest involves activation of ATM/p53/p21(cip1/waf1) pathways and delayed cyclin B1 nuclear translocation. Asian Pac J Cancer Prev 15(9): 4101–4107.
Citing Literature
